BioSpace News Archive

According to Latest Report Study, the global alcoholic hepatitis therapeutics market size was valued at US$ 0.7 billion in 2021 and is expected to reach US$ 1.3 billion by 2030 expanding at a CAGR of 6% from 2022 to 2030.

According to latest report, the global antiviral combination therapies market value was reached at US$ 42.85 billion in 2021 and projected to hit US$ 71.2 billion by 2030 with expanding CAGR of 5.8% from 2022 to 2030.

Himalaya Therapeutics today provided clinical program updates for both mecbotamab vedotin (HTBA3011) and ozuriftamab vedotin (HTBA3021) addressing multiple tumor types as well as updates on CAB-CTLA-4 (HTBA3071).

Cancer gene therapy has gained popularity in the last few years due to its high success rates during clinical and preclinical trials.

According to Latest Report Study, the global central lab market size is predicted to surpass over US$ 4 billion by 2030 and expanding at a noteworthy CAGR of 6.1% from 2021 to 2030.

Bayer announced today that it has received a grant from the Bill & Melinda Gates Foundation.

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that GSK presented positive end of study data from the Phase 2b B-Clear study of bepirovirsen (formerly IONIS-HBVRx), an investigational antisense oligonucleotide treatment for patients with chronic hepatitis B virus (CHB).

PharmaJet®, a company that has developed and commercialized a needle-free platform to more effectively administer drugs and biologics, today announced that their PharmaJet Tropis® Needle-free Injection System (NFIS) will be used in a door-to-door immunization campaign aimed at reducing the outbreak of circulating mutant poliovirus Type 2 (cMPV2).

DynamiCure today announced that it has dosed the first patients in its Phase 1 clinical trial evaluating the safety and anti-tumor activity of the first of the company’s two anti-CD93 monoclonal antibody candidates, DCBY02, in adults with a wide range of advanced cancers.

Anaergia Inc. (“Anaergia” or the “Company”) (TSX: ANRG) will release financial results for the third quarter of 2022 before market open on Thursday, November 10, 2022.